VERDI “Mpox paediatric and adolescent clinical study"

You are invited to take part in a study of mpox in children and adolescents globally. The study aims to collect harmonised data on monkeypox virus infection in these groups to enable epidemiological analysis of the combined dataset.

The state of knowledge regarding the epidemiology, clinical presentation and outcomes of mpox disease in children and adolescents is limited. There is currently a need for a harmonized EU paediatric clinical protocol for standardized collection and analysis of data on monkeypox virus infection in this group.

WHO WE ARE

This study is a Joint EU Clinical Research Initiative which is part of the VERDI (SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts) project, in collaboration with VACCELERATE. VERDI is coordinated by the University of Padova, and this study is sponsored by Fondazione Penta Onlus, both based in Padova, Italy.

We are establishing a standard observational mpox data collection system (for collection of data on both retro- and prospective cases) with the initial goal of describing the presentation, clinical course, and outcomes of children and adolescents (0-17 years old at mpox diagnosis) with laboratory-confirmed MPXV infection.STUDY PROCEDURES

·       Phase 1: starts in December 2022 with collection of anonymised real-world data on children and adolescents with laboratory-confirmed MPXV infection. Requirement for ethics approval dependant on local regulation.

·       Phase 2: starts in March 2023 with establishment of an enhanced observational cohort of paediatric cases with confirmed MPXV infection. This will be a consented study collecting detailed pseudonymised data, including longer term follow-up through data linkage and / or direct patient contact. A site feasibility assessment will be performed prior to joining this phase of the study and local ethics approval will be required.
 
WHO SHOULD PARTICIPATE
All sites:
·       including university, non-academic, tertiary care and community hospitals,
·       with or without prior experience in carrying out research projects,
·       who are or will be taking care of children with confirmed MPX or pediatric MPX contacts

 To get more information please email giorgia.dallavalle@pentafoundation.org

ESWI Respiratory Virus Summit 2023

ESPID are pleased to share Terho Heikkinen will be representing ESPID and participating in a panel in the Respiratory Virus Summit: The Burden of RSV Disease and New Intervention Strategies, More infromation on the Programme, Speakers overview and registrations can be found here. 

Strategic partnership between European Academy of Paediatrics (EAP) and the battery manufacturer, Duracell,

 You may read more about this campaign on the EAP's website here.

ESPID Turkey & Syria Earthquake

 ESPID are deeply saddened by the devastation earthquakes caused in Turkey and Syria, claiming thousands of lives and ESPID are concerned for the potential threat of clusters of infectious diseases.

Our thoughts are with all those affected by the earthquakes and the destruction now faced by survivors of this horrific disaster. To the families across the world who have lost loved ones, we send our condolences.   

Anyone who wishes to offer support to those affected, you can do so through the appropriate organisations or write to admin@espid.org to be directed to these organisations.